Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-2 and leukemia

M Goodman1, L Cabral, P Cassileth

  • 1Hematology-Oncology Division of the University of Miami School of Medicine's Sylvester Comprehensive Cancer Center, FL 33136, USA.

Leukemia
|November 21, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lighting up the structure and electronic properties of α-, β-, γ-Ag<sub>2</sub>WO<sub>4</sub> polymorphs under laser irradiation: a DFT investigation.

Physical chemistry chemical physics : PCCP·2025
Same author

Tuning the magnetic properties of Sn<sub>1-</sub> Ce<sub>4+</sub> Ce<sub>3+</sub> O<sub>2</sub> nanoparticles: an experimental and theoretical approach.

Nanoscale advances·2022
Same author

The Role Of Comorbidities On Outcome Prediction In Acute Burn Patients.

Annals of burns and fire disasters·2022
Same author

The Centre for Data and Knowledge Integration for Health (CIDACS): Linking Health and Social Data in Brazil.

International journal of population data science·2021
Same author

Tailoring the physical and chemical properties of Sn<sub>1-x</sub>Co<sub>x</sub>O<sub>2</sub> nanoparticles: an experimental and theoretical approach.

Physical chemistry chemical physics : PCCP·2020
Same author

Aging and burn: a five-year retrospective study in a major burn centre in Portugal.

Annals of burns and fire disasters·2019
Same journal

Redefining light-chain smoldering multiple myeloma: prevalence and progression risk.

Leukemia·2026
Same journal

Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.

Leukemia·2026
Same journal

Retroperitoneal bulk predicts chylothorax in follicular lymphoma-control requires systemic response.

Leukemia·2026
Same journal

Linperlisib enhances MUC1-Tn CAR T cell efficacy by inhibiting EGR1/DUSP2 axis to prevent CAR T cell exhaustion.

Leukemia·2026
Same journal

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

Leukemia·2026
Same journal

Single-cell architecture of purinergic signaling in human cord blood hematopoietic stem and progenitor cells.

Leukemia·2026
See all related articles

Interleukin-2 shows promise in treating refractory leukemias by boosting immune cells. Further research is needed to understand its clinical benefits and optimal use in leukemia therapy.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Chemotherapy offers moderate success for leukemia treatment.
  • Immune system augmentation shows potential for improved leukemia outcomes.
  • T cell reinfusions demonstrate durable remissions in relapsed chronic myelogenous leukemia.

Purpose of the Study:

  • To evaluate the effectiveness of Interleukin-2 (IL-2) in treating refractory leukemias.
  • To explore the correlation between biologic and clinical effects of IL-2.
  • To investigate the potential role of IL-2 in myeloid leukemias.

Main Methods:

  • Administration of Interleukin-2 to patients with refractory leukemias.
  • Observation of clinical responses and biologic effects of IL-2.

Related Experiment Videos

  • Review of existing evidence on IL-2 in leukemia treatment.

    • Main Results:

    • A limited number of refractory leukemias responded to IL-2 treatment.
    • Clinical activity of IL-2 appears most pronounced in myeloid leukemias.
    • Lack of clear correlation between IL-2's biologic and clinical effects noted.

    Conclusions:

    • Interleukin-2 demonstrates potential as a treatment for certain refractory leukemias.
    • Optimal dosing and administration of IL-2 for leukemia require further investigation.
    • Large randomized studies are essential to define the role of IL-2 in leukemia therapy.